Intravitreal Reinjection of Triamcinolone for Exudative Age-RelatedMacular Degeneration | Clinical Pharmacy and Pharmacology | JAMA Ophthalmology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.153.100.128. Please contact the publisher to request reinstatement.
Clinical Sciences
February 2004

Intravitreal Reinjection of Triamcinolone for Exudative Age-RelatedMacular Degeneration

Author Affiliations

From the Department of Ophthalmology, Faculty of Clinical Medicineof Mannheim, University of Heidelberg, Heidelberg, Germany. The authors haveno relevant financial interest in this article.

Arch Ophthalmol. 2004;122(2):218-222. doi:10.1001/archopht.122.2.218
Abstract

Objective  To evaluate the outcome of repeated intravitreal injections of triamcinoloneacetonide for the treatment of exudative age-related macular degeneration.

Methods  This prospective, comparative nonrandomized clinical interventionalstudy included 13 patients with progressive exudative age-related maculardegeneration with occult, or predominantly occult, subfoveal neovascularization.All patients had shown an increase or stabilization of visual acuity aftera first intravitreal injection of 25 mg of triamcinolone acetonide. They receiveda second intravitreal injection of 25 mg of triamcinolone acetonide 3.1 to18 months after the first injection. Mean ± SD follow-up time afterthe second injection was 5.2 ± 3.6 months (median, 5.3 months). A controlgroup included 24 patients with exudative age-related macular degenerationwho did not receive treatment for their maculopathy. The main outcome measureswere visual acuity and intraocular pressure.

Results  In the study group, mean ± SD visual acuity increased significantly(P = .005 and P = .003,respectively) from 0.17 ± 0.11 to 0.32 ± 0.26 and from 0.15± 0.14 to 0.23 ± 0.19, respectively, after the first and secondinjections. An increase in visual acuity was found for 10 patients (77%) afterthe first and second injections. In the control group, visual acuity did notvary significantly during follow-up (P = .81). Thedifference in change in visual acuity between the study group and controlgroup was significant (P = .01 [Snellen lines] and P = .05 [logMAR units]). The peak in visual acuity and,in a chronologically parallel manner, the peak in intraocular pressure elevationoccurred 2 to 5 months after each injection.

Conclusions  Repeated intravitreal injection of 25 mg of triamcinolone acetonidemay lead to an increase in visual acuity in patients with exudative age-relatedmacular degeneration, with the peak in visual acuity and intraocular pressureelevation occurring about 2 to 5 months after each injection.

×